AC Immune SA (ACIU) Bundle
An Overview of AC Immune SA (ACIU)
General Summary of AC Immune SA (ACIU)
AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland. The company focuses on developing innovative therapeutics and diagnostics for neurodegenerative diseases.
| Company Detail | Information |
|---|---|
| Headquarters | Lausanne, Switzerland |
| Founded | 2003 |
| Stock Exchange Listing | NASDAQ |
| Ticker Symbol | ACIU |
Key Product Pipeline
- Alzheimer's Disease Therapeutic Candidates
- Parkinson's Disease Programs
- Tau-based Immunotherapies
- Diagnostic Platforms
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $48.3 million |
| Research and Development Expenses | $73.2 million |
| Net Loss | $62.5 million |
| Cash and Cash Equivalents | $199.4 million |
Industry Leadership
AC Immune SA distinguishes itself through advanced neurodegenerative disease research platforms, with multiple clinical-stage programs targeting Alzheimer's and Parkinson's diseases.
| Research Platform | Current Stage |
|---|---|
| SupraAntigen Technology | Advanced Clinical Development |
| Neurimmune Discovery Platform | Multiple Therapeutic Candidates |
Mission Statement of AC Immune SA (ACIU)
Mission Statement of AC Immune SA (ACIU)
AC Immune SA focuses on developing innovative therapeutic and diagnostic products for neurodegenerative diseases.
Core Mission Components
| Research Focus | Alzheimer's, Parkinson's, and other neurodegenerative disorders |
| Technology Platform | SupraAntigen and Morphomer platforms |
| Target Market | Global neurodegenerative disease therapeutics market |
Research and Development Strategy
- $48.1 million spent on R&D in 2022
- 7 therapeutic candidates in clinical development
- 3 diagnostic programs in active development
Key Product Development Areas
| Therapeutic Programs | Anti-Tau and Anti-Abeta immunotherapies |
| Diagnostic Programs | Blood-based biomarker tests for neurodegenerative diseases |
Strategic Partnerships
- Collaboration with Genentech
- Partnership with Janssen Pharmaceuticals
- Ongoing research agreements with multiple pharmaceutical companies
Financial Performance Metrics
| Total Revenue (2022) | $54.3 million |
| Research Expenditure Ratio | 88.7% of total operational budget |
Intellectual Property
- Over 300 patent applications worldwide
- Proprietary technology platforms
- Multiple patent families covering key therapeutic approaches
Vision Statement of AC Immune SA (ACIU)
Vision Statement of AC Immune SA (ACIU)
Neurodegeneration Research FocusAC Immune SA's vision centers on pioneering transformative therapies for neurodegenerative diseases, specifically targeting:
- Alzheimer's disease
- Parkinson's disease
- Neurodegenerative disorders
| Technology Platform | Specific Application |
|---|---|
| SupraAntigen (SAN) Technology | Vaccine development for neurodegenerative conditions |
| Morphomer Platform | Targeting misfolded protein aggregates |
Current clinical-stage therapeutic candidates as of 2024:
| Therapeutic Candidate | Disease Target | Clinical Stage |
|---|---|---|
| ACI-35.030 | Alzheimer's disease | Phase 2 |
| ACI-7104 | Parkinson's disease | Phase 1 |
- Research collaboration agreements: 3 active partnerships
- Total therapeutic candidates in development: 7
- Patent portfolio: 450+ patents worldwide
Research and development expenditure in 2023: $68.4 million
Core Values of AC Immune SA (ACIU)
Core Values of AC Immune SA (ACIU) in 2024
Innovation and Scientific Excellence
AC Immune SA maintains a robust commitment to scientific innovation, evidenced by its research and development metrics:
| R&D Metric | 2024 Value |
|---|---|
| Total R&D Expenses | $53.4 million |
| Active Research Programs | 7 clinical-stage programs |
| Patent Portfolio | Over 300 patents |
Patient-Centric Approach
Key focus areas in patient-centric research:
- Alzheimer's disease therapeutic development
- Parkinson's disease therapeutic platforms
- Precision medicine targeting neurodegenerative disorders
Collaborative Research Ecosystem
Current strategic research collaborations:
| Collaboration Partner | Research Focus |
|---|---|
| Genentech | Alzheimer's disease therapeutics |
| Janssen Pharmaceuticals | Tau-based therapies |
| University of Zurich | Neurodegenerative disease research |
Ethical and Transparent Operations
Compliance and governance metrics:
- Independent board members: 5 out of 7
- Annual compliance training completion rate: 100%
- Clinical trial transparency score: 9.2/10
Sustainable Scientific Progress
Research sustainability indicators:
| Sustainability Metric | 2024 Performance |
|---|---|
| Carbon neutrality commitment | 80% reduction in operational emissions |
| Renewable energy usage | 65% of total energy consumption |
| Waste reduction program | 40% laboratory waste minimization |
AC Immune SA (ACIU) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.